net dbt
po updat modestli market
po updat modestli market move reiter buy
updat po reiter buy rate
po updat continu reflect blend dcf new target pe
multipl account recent market move fundament
rate share buy three reason
de-risk cash gener immunolog franchis abil leverag market
lead posit go forward patent estat like block us biosimilar
strong pipelin next gener agent valuat undemand
trade discount us major forward pe favor outlook
catalyst cumul drive multipl re-rat includ elagolix approv
endometriosi phase data uterin fibroid venclexta approv second line
cll favor launch posit phase data upadacitinib ra
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
research-bas global pharmaceut
busi spun abbott
develop market drug area
immunolog virolog oncolog
buy thesi base street
underappreci strength humira
formul patent combin patent
litig timelin give us confid
see us biosimilar
optimist commerci potenti
next-gener immunolog
signific negoti leverag biosimilar
develop think like lead
patent settlement push biosimilar
launch
price object po base blend valuat risk-adjust dcf
target price-to-earnings multipl non-gaap ep estim
target multipl in-lin peer averag assum wacc
termin growth rate believ dcf assumpt reason
minim contribut pipelin valid late-stag
clinic studi histor trade discount peer price-to-earnings
owe humira biosimilar risk multipl expand last month
believ warrant base humira settlement pipelin readout risk
earlier-than-anticip launch humira biosimilar us clinic pipelin
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
